Justices Won't Review Do-Overs Of Whistleblower FCA Cases

Law360 (January 11, 2021, 4:54 PM EST) -- The U.S. Supreme Court on Monday shot down Bristol-Myers Squibb and Sanofi's challenge to a decision that allowed New Mexico to proceed with allegations of unlawful drug marketing even though a whistleblower lost a suit with the same facts.

The justices denied a petition by drugmakers Bristol Myers Squibb Co. and Sanofi-Aventis US LLC, which had argued that there is "an important and growing disagreement" among the courts on whether a whistleblower's loss in a False Claims Act case means the government can't pursue the same allegations. The high court gave no reasoning behind its denial.

"Bristol Myers Squibb and Sanofi...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!